Literature DB >> 3085266

The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.

E K Kruithof, C Tran-Thang, F Bachmann.   

Abstract

We have compared the ability of a plasminogen activator inhibitor (PA-inhibitor) in human plasma, to form complexes with radioiodinated tissue-type plasminogen activator (t-PA) and high molecular weight urokinase (HMr-UK). Addition of 125I-t-PA (final concentration 10 IU/ml) or of 125I-HMr-UK (2 IU/ml) to a plasma containing 33 U/ml of PA-inhibitor resulted in the rapid formation of a 110,000 Mr complex of 125I-t-PA or a 95,000 Mr complex of 125I-HMr-UK with PA-inhibitor. Upon prolonged incubation of the plasma with 125I-HMr-UK a secondary complex of a Mr of 88,000 was observed, which probably derives from limited degradation of the 95,000 complex. Preincubation of the plasma with unlabelled t-PA, HMr-UK or LMr-UK at higher concentrations prevented the subsequent formation of complexes between radiolabelled PAs and the PA-inhibitor. These results thus demonstrate that t-PA and UK form complexes with the same PA-inhibitor. The rate of complex formation of 125I-t-PA or of 125I-HMr-UK with the plasma PA-inhibitor was similar (second order rate constant of association with PA-inhibitor in the order of 10(7) M-1s-1).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085266

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 2.  Modern treatment of pulmonary embolism.

Authors:  C M Kessler
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

4.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

5.  Disappearance and formation rates of microaneurysms in early diabetic retinopathy.

Authors:  T Hellstedt; I Immonen
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells.

Authors:  Byung-Koo Yoon; Young-Hee Kang; Won-Jong Oh; Kyungwon Park; Dong-Yun Lee; Dooseok Choi; Duk-Kyung Kim; Youngjoo Lee; Mee-Ra Rhyu
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

7.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.

Authors:  O Saksela; D Moscatelli; D B Rifkin
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

8.  Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Authors:  Katherine A Vousden; Tomas Lundqvist; Bojana Popovic; Brian Naiman; Alan M Carruthers; Philip Newton; Daniel J D Johnson; Anja Pomowski; Trevor Wilkinson; Patrick Dufner; Isabelle de Mendez; Philip R Mallinder; Clare Murray; Martin Strain; Jane Connor; Lynne A Murray; Matthew A Sleeman; David C Lowe; James A Huntington; Tristan J Vaughan
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

9.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.